Comparison between house dust mite sublingual immunotherapy and subcutaneous immunotherapy in patients who received subcutaneous immunotherapy in maintenance phase
Not Applicable
- Conditions
- The global allergic diesae is likely to increase incidence and complications,especially allergic rhinitis and asthma. Management of allergic disease are avoidance of precipritating casue,SWITCH SCIT SLIT HDMmedication
- Registration Number
- TCTR20200606002
- Lead Sponsor
- Department of medicine, Phramongkutklao hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
1. Age of 18-65 years
2. diagnosed allergic rhinitis and/or asthma
3. In asthma patient; FEV1 more than 70% predicted
4. skin prick test or specific IgE positive to Der p or Der f
5. on going SCIT in maintenance phase during 2 month to 3 years
Exclusion Criteria
1.history of allergic to SLIT
2. uncontrolled asthma within 3 months
3. Autoimmune disease
4. active upper respiratory tract infection
5. psychiatric disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method clinical efficacy of HDM SLIT and SCIT in maintenance phase 3 months total nasal symptoms score, Total medication score, asthma control test score
- Secondary Outcome Measures
Name Time Method aboratories about the efficacy of HDM SLIT and SCIT in maintenance phase 3 months regulartory T cell